

1 **Full title: Epidemiology and burden of respiratory syncytial virus in Italian**
2 **adults: A systematic review and meta-analysis**

3
4 **Short title: Epidemiology and burden of RSV in Italian adults**

5
6 Alexander Domnich¹, Giovanna Elisa Calabrò²

7
8 1 Hygiene Unit, San Martino Policlinico Hospital-IRCCS for Oncology and Neurosciences, Genoa, Italy,

9 2 Section of Hygiene, Department of Life Sciences and Public Health, Università Cattolica del Sacro Cuore,
10 Rome, Italy.

11
12 **Correspondence:** Alexander Domnich, San Martino Policlinico Hospital-IRCCS for Oncology and
13 Neurosciences, Largo Rosanna Benzi 10, 16132 Genoa, Italy. Email: alexander.domnich@hsanmartino.it

14 **Abstract**

15

16 **Objective**

17

18 Respiratory syncytial virus (RSV) is a common respiratory pathogen not only in children, but also in adults.
19 Country-specific data on the epidemiology and burden of disease are essential for policy decisions. In view of
20 a recent authorization of adult RSV vaccines, we aimed to comprehensively collect and assess evidence on
21 the epidemiology and burden of RSV in Italian adults.

22

23 **Methods**

24

25 A systematic literature review was conducted according to the available guidelines. Random-effects
26 proportional meta-analysis was performed to obtain pooled estimates and the observed heterogeneity was
27 investigated by using both subgroup and meta-regression analyses.

28

29 **Results**

30

31 A total of 35 studies were identified. RSV seasonal attack rates ranged from 0.8 ‰ in community-dwelling
32 older adults to 10.9% in hematological outpatients. On average, 4.5% (95% CI: 3.2–5.9%) of respiratory
33 samples tested positive for RSV. This positivity prevalence was higher in older adults (4.4%; 95% CI: 2.8–
34 6.3%) than in working-age adults (3.5%; 95% CI: 2.5–4.6%) and in outpatient (4.9%; 95% CI: 3.1–7.0%) than
35 inpatient (2.9%; 95% CI: 1.5–4.8%) settings. Study location and sample size were also significant predictors
36 of RSV detection frequency. The pooled estimate of in-hospital mortality was as high as 7.2% (95% CI: 4.7–
37 10.3%). However, other important indicators of the diseases burden, such as complication and hospitalization
38 rates, are missing.

39

40 **Conclusion**

41

42 RSV poses a measurable burden on Italian adults, especially those of older age and with some co-morbidities.
43 Policy makers should give priority to health technology assessment of the novel RSV vaccines.

44

- 45 **Keywords:** Respiratory syncytial virus; RSV; Epidemiology; Burden of disease; Adults; Older adults;
- 46 Systematic review; Italy

47 **1. Introduction**

48

49 Together with seasonal influenza, respiratory syncytial virus (RSV) is a leading cause of respiratory infections
50 and is responsible for a significant socioeconomic burden in all age groups, especially at the extremes of age
51 [1,2]. A recent modelling study [3] has estimated that on average, a total of 158,229 RSV-associated
52 hospitalizations among European adults occur annually and 92% of these concerns the elderly. Contrary to
53 young children, mortality attributable to RSV increased in both working-age and older adults [4].

54 Several systematic reviews and meta-analyses (SRMAs) [5–10] have investigated global epidemiology and
55 burden of RSV in (older) adults. These reviews have advocated high incidence, hospitalization, mortality and
56 case-fatality rates of RSV [5–10], which seem similar to seasonal influenza [9], and pointed out a substantial
57 case under-ascertainment [10]. Moreover, there was a large between-country variation in estimates of the
58 burden of disease (BoD) [6], which is driven by numerous factors, from climatic conditions [11] to the features
59 of surveillance systems in place [12]. Notably, the available SRMAs [5–10] have identified only up to six studies
60 conducted in Italy.

61 Two vaccines have been recently authorized to prevent lower respiratory tract disease (LRTD) caused by RSV
62 in adults aged ≥ 60 years [13]. This age indication will be likely extended to younger individuals in the upcoming
63 years. Some countries have already established RSV immunization policies. In the United States (US), a single
64 dose of RSV vaccine is recommended to adults ≥ 60 years, as a part of shared clinical decision-making
65 between patient and healthcare provider [14]. In the United Kingdom (UK), RSV vaccination is currently
66 advised for older adults aged ≥ 75 years, being the most cost-effective option [15]. By contrast, as of November
67 2023, no recommendations have been issued in Italy.

68 Understanding country-specific BoD is a key driver for policy decisions on the introduction of new vaccines
69 [16]. A systematic appraisal of the burden of RSV enables policy makers, health professionals and other
70 relevant stakeholders to make informed decisions regarding the recently available vaccines. In this regard,
71 SRMAs on different BoD indicators are important in the description of spatiotemporal distribution and variations
72 between population subgroups potentially targeted by the novel preventive measures [17,18]. Systematically
73 appraised country-specific BoD indicators are also essential for all types of pharmaco-economic models.

74 In Italy, a recent review [19] has assessed RSV BoD in pediatric outpatients, also with the aim to inform
75 decision makers on the recent availability of a monoclonal antibody for RSV prevention in neonates. By
76 including six studies, the authors found that 18–41% of children with respiratory infections were positive for
77 RSV. Conversely, no reviews have systematically assessed burden of RSV in Italian adults. Indeed, RSV

78 epidemiology is highly age-dependent, which hinders transferability of pediatric estimates to older populations.
79 Furthermore, as we mentioned earlier, the available global-level reviews [5–10] were able to identify only a
80 limited number of Italian studies. In this SRMA, we aimed to comprehensively collect and analyze available
81 data on RSV epidemiology and BoD in Italian adults with the ultimate goal of informing and supporting National
82 and local decision makers on the planification and implementation of vaccination strategies.

83

84 **2. Materials and methods**

85

86 **2.1. Reporting standards and protocol**

87

88 PRISMA (preferred reporting items for SRMAs) statement [20] was adopted as a reporting standard (S1 Table).
89 Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence
90 and cumulative incidence data developed by the Joanna Briggs Institute (JBI) [21] was also consulted. The
91 study protocol was prospectively registered [22] and no amendments to the original protocol were made.

92

93 **2.2. Eligibility criteria**

94

95 All types of observational studies and published in any modality (e.g., peer-reviewed article, preprint,
96 conference abstract, etc.) were potentially eligible. The CoCoPop (condition, context, and population)
97 approach [21] was used to formulate the inclusion criteria. In particular, the condition of interest was RSV
98 infection detected by any laboratory technique, including reverse-transcription polymerase chain reaction (RT-
99 PCR), culture, immunofluorescence assay (IFA) and rapid antigen tests. Moreover, RSV-specific International
100 Statistical Classification of Diseases and Related Health Problems (ICD) diagnosis codes (see below) were
101 also considered a good proxy for the true RSV infection, since their specificity is as high as 99.6–99.8% [23,24].
102 For the context, we considered studies conducted in Italy, in any setting (outpatient, inpatient or mixed), time
103 and calendar period. Population consisted of adults defined as individuals aged ≥ 14 years, independently of
104 their health conditions. Any reason or clinical entity [e.g., influenza-like illness (ILI), acute respiratory infection
105 (ARI), severe ARI (SARI), clinical request for differential diagnosis] that triggers collection of biological samples
106 (upper respiratory tract specimens including naso/oropharyngeal and nasal swabs; lower respiratory tract
107 specimens including sputum, bronchoaspirates and bronchoalveolar lavage fluids) was eligible.

108 The following were set as exclusion criteria: (i) modeling, pharmaco-economic and similar studies with no
109 original data; (ii) insufficient data on RSV; (iii) studies on general population with no separate data for adults;
110 (iv) multi-country studies with no separate data for Italy; (v) redundant publications.

111

112 **2.3. Study endpoints**

113

114 RSV attack rate (cumulative incidence) was defined as the occurrence of laboratory-confirmed RSV detection
115 in a population (symptomatic, asymptomatic or both) and in a specific period. RSV positivity prevalence was
116 defined as proportion of RSV detections to the number of subjects tested. Prevalence of viral co-detections
117 was described as number of samples tested positive for both RSV and any other respiratory virus to the total
118 number of RSV-positive samples. Case-complication rate was defined as proportion of subjects who tested
119 positive for RSV and developed ≥ 1 complication, such as pneumonia, exacerbation of chronic obstructive
120 pulmonary disease (COPD), asthma, congestive heart failure, and other. As for drug use indicators, we
121 considered frequency of antibiotic prescriptions among RSV-positive subjects. For what concerns inpatient
122 outcomes, crude hospitalization, case-hospitalization (i.e., proportion of RSV-positive individuals who were
123 hospitalized) rates, length of stay [mean with standard deviation (SD) or median with interquartile range (IQR)]
124 and frequency of admission to intensive care units (ICUs) were of interest. Analogously, crude, in-hospital, 30-
125 day mortality and case-fatality rates were eligible. For the indicators based on hospital discharge records
126 (HDRs) or death certificates, we considered only RSV-specific codes, namely RSV pneumonia (ICD-9: 480.1;
127 ICD-10: J12.1), acute bronchiolitis due to RSV (ICD-9: 466.11; ICD-10: J21.0), acute bronchitis due to RSV
128 (ICD-10: J20.5), and RSV as the cause of diseases classified elsewhere (ICD-9: 079.6; ICD-10: B97.4).

129 When possible, all study endpoints were described overall, by age-group (working-age and older adults), RSV
130 subtype (A and B) and season.

131

132 **2.4. Search strategy**

133

134 The automatic search was performed on 22 November 2023 in the following databases: (i) MEDLINE via Ovid;
135 (ii) Biological Abstracts via Ovid; (iii) Global Health via Ovid; (iv) Scopus and (v) Web of Science. In order to
136 increase sensitivity, no filters or other restrictions (e.g., language or publication year) were applied. The search
137 script considered both MeSH (medical subject headings) and text-wide terms and is reported in S2 Table.

138 We then performed a manual search through several modalities. First, the reference lists of the available
139 global-level SRMAs [5–10] were checked. Second, a backward cross-reference checking of the included
140 studies was carried out. Third, a forward citation search by using Google Scholar (<https://scholar.google.com/>)
141 was conducted, as this search engine is better suited for identifying grey literature sources [25]. Fourth,
142 periodic reports of the Italian surveillance reports on influenza and other respiratory viruses
143 (<https://respirnet.iss.it>) were examined. Finally, we screened abstract books and proceedings of some
144 relevant conferences, including ECCMID (European Society of Clinical Microbiology and Infectious Diseases),
145 ESWI (European Scientific Working Group on Influenza) and ReSViNET.

146

147 **2.5. Study selection**

148

149 Results produced by the automatic search were merged into a single spreadsheet and duplicates were
150 removed. The resulting list of unique records underwent screening by assessing titles and/or abstracts and
151 clearly irrelevant citations were discarded. Full texts of potentially pertinent publications were then downloaded
152 and assessed for the above-described eligibility criteria. Study selection was finalized by performing the
153 manual search, as described earlier. The entire process of study selection was performed by both reviewers,
154 each working independently; eventual disagreements were solved by consensus.

155

156 **2.6. Data extraction and abstraction**

157

158 The following data were extracted: (i) full citation record; (ii) study location; (iii) study period; (iv) study design;
159 (v) study setting; (vi) main characteristics of the study population; (vii) sample size; (viii) funding source; (ix)
160 eligibility criteria and case definitions; (x) methods used for case ascertainment; (xi) numerators and
161 denominators used to compute the endpoints of interest described above; (xii) other potentially relevant
162 information.

163 On the basis of period, studies were dichotomized on whether they overlapped with the COVID-19 pandemic,
164 which had a significant impact on the circulation of RSV and other respiratory viruses. In particular, the northern
165 hemisphere winter season 2020/2021 was characterized by a very limited circulation of RSV [19,26]. Estimates
166 for that season were extracted, but not included in the quantitative synthesis. Starting from the 2021/2022
167 season, RSV returned to the epidemiological scene [26] and therefore estimates from 2021/2022 onwards
168 were fully considered. Multi-season studies that reported separate seasonal data were considered as distinct

169 estimates [27]. Moreover, we distinguished between year-around studies and those conducted during a typical
170 RSV season, in which the probability of RSV detection is much higher [28]. We defined RSV epidemic season
171 as a period between October and April [26].

172 On the basis of sample size, studies were median split. Regions of were categorized into three macro-areas
173 of North (Aosta Valley, Liguria, Lombardy, Piedmont, Emilia-Romagna, Friuli-Venezia Giulia, Trentino-South
174 Tyrol, Veneto), Center (Lazio, Marche, Tuscany, Umbria) and South (Abruzzo, Apulia, Basilicata, Calabria,
175 Campania, Molise, Sicily, Sardinia).

176 Missing data on relevant numerators and/or denominators were handled as follows. First, the corresponding
177 author was contacted for clarification. In case of no reply, these data were imputed from the available
178 percentages and/or by extracting data from figures using the WebPlotDigitizer v.4.6 software
179 (<https://automeris.io/WebPlotDigitizer>). Data were extracted by AD and then validated by GEC.

180

181 **2.7. Critical appraisal**

182

183 The JBI checklist for prevalence studies [21] was used to assess quality of the included studies. It was
184 assessed independently by both reviewers and eventual conflicts were solved by consensus. Item 9 of the JBI
185 checklist on the response rate was judged irrelevant for this study. Owing to a limited information available,
186 risk of bias of conference abstracts, letters to the editor, short communications and similar was not assessed.

187

188 **2.8. Data synthesis**

189

190 Tabulated data were first reassumed qualitatively and by visualizing forest plots. For quantitative synthesis, a
191 proportional meta-analysis was undertaken according to the available recommendations [18,21]. As
192 heterogeneity was expected to be high, random-effects (RE) models with double arcsine transformation to
193 stabilize variances were used. Pooled estimates were expressed as proportions with 95% Clopper-Pearson
194 confidence intervals (CIs). Heterogeneity was quantified by means of the τ^2 and I^2 statistics. Notably, high I^2
195 values do not necessarily mean that the data are inconsistent, as true heterogeneity is expected in prevalence
196 estimates due to spatiotemporal differences [18]. The 95% prediction intervals (PIs) were also computed. As
197 recommended, publication bias was not formally assessed, since there is no consensus about what a positive
198 result in meta-analyses of proportions is [18].

199 To investigate the sources of heterogeneity across studies, both subgroup and meta-regression analyses were
200 performed. In particular, the subgroup analysis was performed by age-group (working-age and older adults),
201 setting (outpatient, inpatient and mixed) and study period in relation to the COVID-19 pandemic (before and
202 after the 2020/2021 season). The meta-regression modeling was then conducted to examine the influence of
203 study characteristics on the RSV-related endpoints. This latter was performed only when ≥ 10 estimates were
204 available [29]. A leave-one-out sensitivity analysis was finally conducted to check the robustness of pooled
205 estimates.

206 Meta-analysis was performed in R (R Foundation for Statistical Computing; Vienna, Austria) package “Meta”
207 v. 6.5-0.

208

209 **3. Results**

210

211 **3.1. Characteristics of the included studies**

212

213 The automatic search generated 312 records, of which 171 were duplicates. Following screening of 141
214 records, 37 were judged potentially eligible. Twelve studies were excluded with reasons and are reported in
215 S3 Table. Manual search identified further 12 studies and therefore the final list was composed of 35 studies
216 corresponding to 37 publications [30–66]. Notably, results relative to a retrospective cohort (henceforth referred
217 to as “Boattini 2021–2023”) were presented in three different publications [64–66]. Following correspondence
218 with the corresponding author, who provided additional data, it was decided to include all these records.
219 Moreover, relevant data (not reported within the article) were also obtained from other two corresponding
220 authors [55,59]. The entire study selection process is reported in Fig 1.

221

222 **Fig 1. PRISMA flow diagram of the study selection process.**

223

224 Most (83%; 29/35) studies included were full-length articles, while the remaining six were conference abstracts
225 [45,47], letters to editor [43,57] and short papers [31,39]. Principal characteristics of the studies are
226 summarized in Table 1. Briefly, the studies covered a period from the 2001/2002 season to the 2022/2023
227 season and most (63%; 22/35) were conducted in the north of Italy. Approximately half (49%; 17/35) of the
228 studies investigated more than one RSV season and the period of nine (26%) studies overlapped with the
229 COVID-19 pandemic. Design of the majority of studies was judged cross-sectional (54%; 19/35) or surveillance

230 (29%; 10/35) and the median sample size was 328 (range 43–28,500) patients. The study population was
 231 composed of outpatients, inpatients and mixed groups in 20% (7/35), 37% (13/35) and 31% (11/35) of studies
 232 respectively; the remaining four (11%) studies were focused on hematological [43–45] and cystic fibrosis [57]
 233 in-/outpatients. The setting of these latter four studies was therefore categorized as “immunocompromised
 234 patients”. All but one studies used at least one laboratory assay (mostly RT-PCR) for RSV detection. The
 235 remaining study [35] analyzed RSV-specific HDRs. Within laboratory-based studies (n = 34), there was a high
 236 level of heterogeneity in terms of clinical entity triggering the specimen collection, especially in mixed and
 237 hospital settings. Six out 7 (86%) outpatient studies enrolled ILI patients. ILI and SARI were more frequently
 238 defined according to the European criteria (S4 Table). Out-of-season samples were frequent (38%; 13/34) and
 239 most studies analyzed only (56%; 19/34) upper respiratory tract specimens. The majority (74%; 26/35) of
 240 studies were funded by public institutions.

241

242 **Table 1. Characteristics of the studies included.**

243

Study [Ref]	Study period	Design	Region (area)	Age, years ^a	Setting	Biological sample trigger or testing reason	Sample size ^a	Case ascertainment (specimen type)	Out-of-season samples	Funding
Rovida 2005 [30]	10/2001–05/2002	Cross-sectional	Lombardy (North)	≥16	Inpatient	ARI	73	RT-PCR and monoclonal antibodies (U)	Yes	Public
Minosse 2008 [31]	04/2004–05/2005	Surveillance	Lazio (Center)	≥18	Inpatient	Respiratory diseases (ARI, COPD, pneumonia)	433	RT-PCR (L)	Yes	Public
Puzzelli 2009 [32]	11/2004–04/2007	Surveillance	Lazio (Center),	≥14	Outpatient	ILI	356	RT-PCR (U)	No	Public

			Campani a (South)							
Costa 2007 [33]	05/2005– 10/2005	Cross- sectional	Piedmon t (North)	≥17	Mixed	Clinical request	46	Culture (L)	Yes	NA
Gerna 2009 [34]	11/2006– 05/2007	Cross- sectional	Lombard y (North)	≥18	Mixed	ARI	244	RT- PCR (U/L)	Yes	Public
Cocchio 2023 [35]	01/2007– 12/2021	Cross- sectional	Veneto (North)	≥50 ^b	Inpatient	–	250	RSV- specific HDRs (NA)	–	Public
Gambarin o 2009 [36]	Presumab ly 2008	Cross- sectional	Piedmon t (North)	≥16	Inpatient	Respiratory conditions	324	RT- PCR (L)	Yes	Public
Paba 2014 [37]	02/2009– 05/2011	Validation of an assay	Lazio (Center)	≥16	Mixed	ILI	178	RT- PCR (U/L)	Yes	Public
Pierangeli 2011 [38]	02/2009– 03/2010	Cross- sectional	Lazio (Center)	≥18	Mixed	Fever at ED admission or in the preceding 5 days and ≥1 respiratory diagnosis (ICD-9: 462, 466.0, 485, 480–486, 786.0, 786.2, 786.5, 793.1, 487)	238	RT- PCR (U)	No	Public
Nisii 2010 [39]	05/2009– 12/2009	Cross- sectional	Lazio (Center)	≥16	Mixed	ILI	544	RT- PCR (U)	Yes	NA
Tramuto 2016 [40]	07/2009– 12/2012	Cross- sectional	Sicily (South)	≥15	Inpatient	SARI with ICU admission	192	RT- PCR (U/L)	Yes	Public

Piralla 2017 [41]	11/2009–04/2016	Cross-sectional	Lombardy (North)	≥18	Inpatient	CAP with ICU admission	376	RT-PCR (U/L)	No	Public
Ansaldi 2012 [42]	11/2010–04/2011	Prospective cohort	Liguria (North)	≥60	Outpatient	ILI	2551 (45 tested for RSV)	RT-PCR (U)	No	NA
Bigliardi 2015 [43]	2010–2014	Cross-sectional	Emilia-Romagna (North)	≥15	Immuno-compromised patients ^c	LRTD	144	Probably RT-PCR (L)	Yes	Public
Mikulska 2014 [44]	01/2011–03/2011	Prospective cohort	Liguria (North)	≥18	Immuno-compromised patients ^c	ILI, ARI, any new symptom and screening	193	RT-PCR (U/L)	No	Public
Passi 2019 [45]	01/2011–03/2019	Surveillance	Lombardy (North)	≥18	Immuno-compromised patients ^c	URTI	151	RT-PCR (U)	Yes	NA
Pellegrinelli 2020 [46]	11/2014–04/2018	Surveillance	Lombardy (North)	≥16	Outpatient	ILI	706	RT-PCR (U)	No	Public
Costa 2023 [47]	11/2014–04/2022	Cross-sectional	Liguria (North)	≥18	Mixed	Clinical request	11,658	RT-PCR (U/L)	No	Public
Tramuto 2021 [48]	10/2015–04/2020	Cross-sectional	Sicily (South)	>18	Mixed	ILI (outpatients), SARI (inpatients)	3727	RT-PCR (U/L)	No	Private
Leli 2021 [49]	01/2016–06/2020	Cross-sectional	Piedmont (North)	≥18	Mixed	Respiratory infection	375	RT-PCR (U)	Yes	Public
Ciotti 2020 [50]	10/2016–03/2019	Cross-sectional	Lazio (Center)	≥18	Inpatient	Suspected or documented respiratory virus infection	539	RT-PCR (U/L)	Yes	Public

De Francesco 2021 [51]	01/2017–05/2021	Cross-sectional	Lombardy (North)	≥18	Inpatient	SARI	3974	RT-PCR (U/L)	Yes	Public
Galli 2020 [52]	11/2018–04/2019	Validation of swab self-sampling	Lombardy (North)	≥18	Outpatient	ILI	262	RT-PCR (U)	No	Public
Domnich 2024 [53]	11/2018–03/2020	Surveillance	Liguria (North)	≥18	Outpatient	ILI	1240	RT-PCR (U)	No	Public and private
Spagnuolo 2021 [54]	01/2019–02/2019	Cross-sectional	Lazio (Center)	>18	Inpatient	CAP with ED admission	75	RT-PCR (U)	No	NA
Sberna 2022 [55]	10/2019–12/2021	Cross-sectional	Lazio (Center)	≥18	Inpatient	SARI	557	RT-PCR (U)	No	Public
Pierangeli 2022 [56]	12/2018–04/2019	Surveillance	Lombardy, South Tyrol (North), Veneto, Marche, Lazio (Center) ^d	≥16	Mixed	ILI (Lombardy) or clinical request (other regions)	Unclear ^e	RT-PCR (U/L)	No	Public
Scagnolari 2020 [57]	11/2019–03/2020	Retrospective cohort	Lazio (Center)	>18	Immuno-compromised patients ^f	Medically attended respiratory disease or screening	183	RT-PCR (U)	No	Public
Galli 2021 [58]	11/2019–04/2020	Surveillance	Lombardy (North)	≥15	Outpatient	ILI	401	RT-PCR (U)	No	Public
Treggiari 2022 [59]	11/2019–01/2022	Cross-sectional	Veneto (North)	>18	Mixed	Clinical request	ca 28,500 ^g	RT-PCR (U)	No	Public
Calderaro 2021 [60]	12/2019–03/2020	Surveillance	Emilia-Romagna (North)	≥18	Mixed	Clinical request	332	RT-PCR, IFA, culture (U/L)	No	Public
Milano 2023 [61]	11/2021–04/2022	Surveillance	Tuscany (Center)	≥18	Inpatient	SARI	129	RT-PCR (U)	No	Public and private

Panatto 2023 [62]	12/2021– 03/2022	Surveillance	Liguria (North)	≥18	Outpatient	Any respiratory symptom	1213	RT- PCR (U)	No	Private
Santus 2023 [63]	10/2022– 03/2023	Cross- sectional	Lombardy (North)	≥18	Inpatient	ILI at ED visit	717	RT- PCR (U)	No	Public
Boattini 2021– 2023 [64– 66]	10/2017– 04/2019	Retrospective cohort	Piedmont (North)	≥18	Inpatient	LRTD	43	RT- PCR (U)	No	Public

244 ^a In studies that enrolled also children, only adult individuals were considered; ^b Age-group 5–49 years was excluded; ^c All patients had
245 hematological conditions; ^d The study had also a center in Emilia-Romagna, which enrolled only young children 0–3 years; ^e A total of
246 11,577 samples were tested for RSV and 423 adults tested positive, the total number of adults tested was not reported; ^f All patients had
247 cystic fibrosis; ^g Number imputed from the available percentages; ARI, Acute respiratory infection; CAP, community-acquired pneumonia;
248 COPD, Chronic obstructive pulmonary disease; ED, Emergency department; HDR, Hospital discharge record; ICD, International Statistical
249 Classification of Diseases and Related Health Problems; ICU, Intensive care unit; IFA, Immunofluorescence assay; ILI, Influenza-like
250 illness; L, Lower respiratory tract specimens; LRTD, Lower respiratory tract disease; NA, Not available; RT-PCR, Reverse-transcription
251 polymerase chain reaction; SARI, Severe Acute respiratory infection; U, Upper respiratory tract specimens; U/L, Upper and lower
252 respiratory tract specimens; URTI, Upper respiratory tract infection.

253

254 Fourteen [32,38,40,41,44,46,48,51,53,58,61–66] out of 29 full-length articles were judged at low risk of bias,
255 while the remaining 15 studies [30,33–37,42,49,50,52,54–56,59,60,64–66] had at least one possible source
256 of bias (S5 Table). The most frequent criticalities concerned insufficient description of patients and setting,
257 inappropriate sample frame and small sample size.

258

259 3.2. RSV attack rate

260

261 Three cohort studies [42,44,57] allowed to determine RSV attack rates. The first one [42] consisted of a cohort
262 of 2551 community-dwelling adults aged ≥60 years who were actively surveilled for ILI between November
263 2010 and April 2011. A total of 45 ILI cases were prospectively identified and these cases were tested in RT-
264 PCR. Other 63 ILI cases were identified retrospectively and thus not tested in RT-PCR. Two out of 45 samples
265 tested positive for RSV, giving a symptomatic attack rate of 0.8 ‰ (95% CI: 0.1–2.8‰). If corrected for under-
266 testing, the cumulative incidence would rise to 1.9 ‰ [42]. Mikulska et al. [44] followed for three months (from
267 January to March 2011) 193 hematological outpatients. A total of 21 swabs tested positive for RSV, with an
268 overall attack rate of 10.9% (95% CI: 6.9–16.2%). Of RSV-positive subjects, 18 (85.7%) were symptomatic,

269 while the remaining three (14.3%) patients were asymptomatic [44]. In a retrospective cohort of adult (>18
270 years) subjects affected by cystic fibrosis [57] eight out of 183 patients tested positive for RSV between
271 November 2019 and March 2020, giving an attack rate of 4.4% (95% CI: 1.9–8.4%). Owing to different study
272 populations, a pooled analysis of these three studies was judged unfeasible.

273

274 **3.3. Prevalence of RSV positivity**

275

276 A total of 85 RSV positivity prevalence estimates were extracted from 32 studies, of which 42 (S6 Table), 21
277 (S7 Table) and 22 (S8 Table) concerned adults of any age, working-age and older adults, respectively. Seven
278 estimates from three studies [51,55,59] covered exclusively the 2020/2021 season and were excluded from
279 the pooled analysis.

280 As shown in Fig 2, the positivity rate in adults of any age ranged from 0.2% to 35.7%. The RE pooled estimate
281 was 4.5% (95% CI: 3.2–5.9%). As expected, the heterogeneity was high ($I^2 = 93.2\%$) and the 95% PI was 0.0–
282 15.9%. Immunocompromised patients showed the highest RSV positivity prevalence of 11.5%. Compared with
283 outpatients (4.9%), inpatients had lower prevalence of RSV (2.9%). Studies conducted in both settings showed
284 an intermediate pooled estimate (3.7%). Omission of single studies did not alter significantly the observed
285 pooled proportions.

286

287 **Fig 2. Forest plot of the random-effects model on RSV positivity prevalence among Italian adults of**
288 **any age, by setting.**

289

290 In the subgroup analysis by age-group (Fig 3), working-age adults showed lower (3.5%) RSV prevalence than
291 older adults (4.4%). RSV detection was more frequent in outpatients than inpatients in both age-specific RE
292 models. RSV detection was also higher in studies conducted before the COVID-19 pandemic than among
293 those performed during the pandemic (i.e., seasons 2021/2022 and 2022/2023) (S1 Fig).

294

295 **Fig 3. Forest plot of the random-effects model on RSV positivity prevalence among Italian working-age**
296 **and older adults, by setting.**

297

298 A meta-regression analysis was conducted to investigate sources of the heterogeneity observed (S9 Table).
299 Apart from the study setting, geographic area and sample size explained some variance in the reported

300 proportions. In particular, compared with northern regions (5.5%), RSV prevalence was as twice as lower in
301 central Italy (2.7%) (S2 Fig). Studies that enrolled <300 patients reported significantly higher prevalence (6.3%)
302 estimates than larger studies (3.0%) (S3 Fig). Publication year, public funding, number of seasons, inclusion
303 of out-of-season samples, specimen type and risk of bias were not associated with the reported RSV detection
304 rate (S9 Table).

305 Data on RSV subtypes was reported in nine studies [39,40,44,46–48,53,56,62]. In these studies, both subtypes
306 co-circulated, although a relative dominance on one subtype over another varied by study period (S10 Table).
307 On average, from 2009 to 2022 both subtypes were detected in almost equal proportions (RE model estimate
308 for RSV B: 56.3%; 95% CI: 44.1–68.1%; $I^2 = 88.4\%$) (S4 Fig).

309 Sanger sequencing was performed in three studies [46,56,62] conducted between 2014/2015 and 2021/2022
310 seasons. During the 2014/15 and 2015/16 seasons, both NA1 and ON1 genotypes of RSV A were circulating
311 [46]. Conversely, starting from the 2017/2018 season all RSV A strains clustered within the ON1 genotype
312 [46,56,62]. All RSV B strains belonged to the BA genotypes [46,56,62].

313

314 **3.4. Prevalence of viral co-detections**

315

316 Thirteen studies reported data on viral co-detections [30,31,36,37,40,47,51,53,54,60–63]. However, only five
317 estimates [37,47,51,53,63] were based on a sufficient (≥ 30) number of RSV-positive samples and were
318 therefore less prone to the small study effect (S11 Table). In these studies, 2.9–18.6% of RSV-positive
319 specimens tested also positive for other respiratory viruses. In the RE model (S5 Fig), the pooled estimate
320 was 8.6% (95% CI: 3.2–15.9%) and the heterogeneity was high ($I^2 = 92.0\%$). Influenza A, seasonal
321 coronaviruses, rhinovirus and parainfluenza viruses were detected more frequently (S11 Table). These results
322 should be interpreted cautiously, since the multiplex RT-PCR panels used differ from the point of view of
323 antigens included.

324

325 **3.5. Severe RSV disease**

326

327 The prespecified outcomes ascribable to severe RSV disease were reported in nine studies
328 [35,41,42,44,50,54,56,63,64–66] (Table 2). Pierangeli et al. [56] reported that 63.1%, 63.3% and 79.3% of
329 adults (both out- and inpatients) aged 16–65, 65–80 and >80 years had antibiotic prescriptions. The study,
330 however, did not reported raw data. In an outpatient cohort (n = 2551) of adults aged ≥ 60 years [42], none of

331 seven cases of community-acquired pneumonia (CAP) tested positive for RSV. Ciotti et al. [50] reported that
 332 among 23 hospitalized cases of viral pneumonia, one (4.3%) was due to RSV. In a multi-season (from
 333 2009/2010 to 2015/2016) study by Piralla et al. [41], the prevalence of RSV among subjects (11/376) with CAP
 334 admitted to ICU was 2.9%. Among 19 RSV-positive hematological patients [44], two (10.5%) developed LRTD
 335 and the 30-day mortality was 0% (95% CI: 0–17.6%). Spagnolello et al. [54] reported that among CAP patients
 336 who referred to emergency departments (n = 75), three tested positive for RSV (4.0%; 95% CI: 1.5–13.1%).
 337 However, the study period was limited to one month only (from 15 January to 22 February 2019) [54].

338

339 **Table 2. Severe RSV-related outcomes, by study.**

340

Study	Age, years	Outcome	% (n/N)	95% CI
Cocchio 2023 [35]	50–69	% in-hospital mortality	4.9 (4/81)	1.4–12.2
	≥70		7.1 (12/169)	3.7–12.1
Piralla 2017 [41]	≥18	% RSV detection in patients with CAP admitted to ICU	2.9 (11/376)	1.5–5.2
Ansaldo 2012 [42]	≥60	% RSV detection in patients with CAP	0 (0/7)	0–41.0
Mikulska 2014 [44]	≥18	% RSV-positive hematological patients who developed LRTD	10.5 (2/19)	1.3–33.1
		% 30-day mortality	0 (0/19)	0–17.6
Ciotti 2020 [50]	≥18	% RSV detection in patients hospitalized for viral pneumonia	4.3 (1/23)	0.1–21.9
Spagnolello 2021 [54]	>18	% RSV detection in ED patients with CAP	4.0 (3/75)	1.5–13.1
Pierangeli 2022 [56]	16–65	% antibiotic use in RSV-positive subjects	63.1 (NA)	NA
	65–80		63.3 (NA)	NA
	>80		79.3 (NA)	NA
Santus 2023 [63]	≥18	% antibiotic use in RSV-positive inpatients	78.7 (48/61)	66.3–88.1
		Median length of hospital stay, days	13 ^a	7–22 ^b
		% RSV-positive inpatients with acute respiratory failure, need for respiratory support, shock, sepsis, ICU admission or in-hospital death	70.5 (43/61)	57.4–81.5
		% RSV-positive inpatients with ICU admission	6.6 (4/61)	1.8–15.9
		% in-hospital mortality	6.6 (4/61)	1.8–15.9
Boattini 2021–2023 [64–66]	≥18	% pneumonia in hospitalized RSV-positive subjects	58.1 (25/43)	42.1–73.0
	≥18	Median length of hospital stay, days	19 ^a	11–30 ^b
	≥65		23 ^a	8–34 ^b
	≥18	% invasive and non-invasive mechanical ventilation in hospitalized RSV-positive subjects	30.2 (13/43)	17.2–46.1
	≥65		27.3 (3/11)	6.0–61.0
	≥18	% in-hospital mortality	16.3 (7/43)	6.8–30.7

	≥65		9.1 (1/11)	0.2–41.3
--	-----	--	------------	----------

341 ^aMedian; ^bInterquartile range; CAP, community-acquired pneumonia; CI, Confidence interval; ED, Emergency department; ICU, Intensive
342 care unit; LRTD, Lower respiratory tract disease; NA, Not available.

343

344 In a hospitalized cohort of RSV-positive adults (n = 61) [63], severe RSV disease (defined as presence of at
345 least one of the following: acute respiratory failure, need for respiratory support, shock, sepsis, ICU admission
346 or in-hospital death) was observed in 70.5% of patients. Antibiotics, systemic steroids, inhaled steroids,
347 oseltamivir and other antivirals were administered to 79.0%, 65.6%, 70.0%, 13.1% and 8.2% of patients
348 respectively. The median length of stay was 13 (IQR: 7–22) days. ICU admission and in-hospital mortality
349 rates were both 6.6%.

350 In a retrospective cohort study by Boattini et al. [64–66], 58.1% (n = 43) of RSV-positive hospitalized adults
351 ≥18 years had radiologically-confirmed pneumonia. The median length of stay for the entire cohort was 19
352 (IQR: 11–30) days, while it increased up to 23 (IQR: 8–34) days for adults aged ≥65 years. A total of 30.2% of
353 subjects needed invasive and non-invasive mechanical ventilation, while the in-hospital mortality was 16.3%.
354 Cocchio et al. [35] analyzed HDRs for RSV-specific ICD-9 codes in Veneto for 15 consecutive years (2007–
355 2021). Of the total of 6961 (5818, 741 and 402 for acute bronchiolitis due to RSV, pneumonia due to RSV and
356 RSV, respectively) hospitalizations, 81 (1.2%; 8, 41 and 32 for acute bronchiolitis due to RSV, pneumonia due
357 to RSV and RSV, respectively) and 169 (2.4%; 31, 74 and 64 for acute bronchiolitis due to RSV, pneumonia
358 due to RSV and RSV, respectively) encounters occurred in adults aged 50–69 and ≥70 years, respectively.
359 The length of stay increased linearly with the increasing age for acute bronchiolitis due to RSV ($\beta = 0.080$;
360 95% CI: 0.059–0.100; $P < 0.001$), pneumonia due to RSV ($\beta = 0.109$; 95% CI: 0.083–0.135; $P < 0.001$) and
361 RSV ($\beta = 0.063$; 95% CI: 0.045–0.081; $P < 0.001$), respectively. Of 23 deaths identified, 73.9% (17/23) were
362 registered in subjects aged ≥50 years. The overall in-hospital mortality rate was 4.9% (4/81; 0%, 7.3% and
363 3.1% for acute bronchiolitis due to RSV, pneumonia due to RSV and RSV, respectively) and 7.1% (12/169;
364 12.9%, 10.8% and 0% for acute bronchiolitis due to RSV, pneumonia due to RSV and RSV, respectively) in
365 subjects aged 50–69 and ≥70 years, respectively.

366 As reported in Table 2, only the outcome of in-hospital mortality was reported in more studies [35,63–66]. In a
367 pooled analysis of four estimates (S7 Fig), the in-hospital mortality was 7.2% (95% CI: 4.7–10.3%). The
368 heterogeneity was relatively low ($I^2 = 30.6\%$) and the 95% PI was 2.2–14.5%.

369

370 4. Discussion

371

372 This SRMA showed that RSV is a frequent respiratory pathogen that poses a measurable burden to Italian
373 adults. However, this BoD is unevenly distributed within the Italian adult population, being higher in older age
374 groups and subjects with underlying health conditions. Our findings may inform principal stakeholders and
375 support policy makers on the introduction of the recently authorized adults RSV vaccines [13] with the aim to
376 ensure effective and coherent resource allocation. Analogously, our study is a good starting point for the
377 upcoming cost-effectiveness and budget impact models. We finally identified principal data gaps, which must
378 be addressed by future research.

379 Our meta-analysis showed that 4.5% of respiratory samples tests positive for RSV and the 95% PI suggested
380 that the next estimate would be between 0% and 16%. This uncertainty reflects both natural between-season
381 variation in the circulation of RSV and characteristics of the population surveilled. We indeed showed that
382 compared with hospitalized individuals, community-dwelling adults had higher positivity prevalence (4.9% vs
383 2.9%). At the same time, compared with working-age adults (3.5%), RSV prevalence was higher in older adults
384 (4.4%) and individuals with immunosuppressive disorders (11.5%). It should be stressed that all these pooled
385 estimates are probably conservative, as a certain level of underestimation is likely for several reasons. First,
386 most primary care studies were conducted within the existing influenza surveillance framework that usually
387 relied on ILI-based case definitions. Different studies [53,67,68] have proved that a significant proportion of
388 RSV-positive adults have no fever and therefore ILI and fever-based case definitions intrinsically
389 underestimate the true incidence of RSV. Second, several hospital-based studies considered only one type of
390 specimen. It has been, for example, shown [69] that adding RT-PCR of sputum to that of nasal or
391 nasopharyngeal swab specimens increases RSV detection by 39–100%. Indeed, RSV may migrate from the
392 upper to lower respiratory tracts and thus RT-PCR performed on naso/oropharyngeal swabs would produce a
393 false-negative result [28].

394 When comparing our results to those of the global-level SRMAs [5–8], we noted both similarities and
395 differences. Nguyen-Van-Tam et al. [7] have reported that the cumulative attack rate of RSV in older adults
396 ranged from 0.27‰ to 108‰. This 400-fold difference [7] is unlikely to be explained by the epidemiology of
397 RSV alone, but is rather linked to the design of single studies. As for RSV incidence in industrialized countries,
398 Shi et al. obtained pooled estimates of 6.7‰ (95% CI: 1.4–31.5‰) [5] and 30.3‰ (95% CI: 5.3–59.9‰) [8] for
399 older and high-risk adults, respectively. In Italy, the available incidence estimates were 1.9 ‰ [42] and 4.4–
400 10.9% [44,57] for older adults and adults with immunosuppressive conditions, respectively. Italian data,
401 however, came from single-season studies and thus affected by RSV circulation patterns in those particular

402 seasons. RSV positivity prevalence appears instead more consistent. For instance, a meta-analysis of
403 European studies by Tin Tin Htar et al. [6] reported that 7% (95% CI: 4–11%), 9% (95% CI: 4–17%) and 10%
404 (95% CI: 5–16%) of ILI/ARI cases in all adults, subjects aged <50 and ≥50 years, respectively, tested positive
405 for RSV. Shi et al. [5] estimated that RSV positivity among hospitalized older adults with ARI was 4.4% (95%
406 CI: 3.0–6.5%). Our meta-analytical proportions were in line with these figures. For what concerns mortality
407 indicators, the pooled in-hospital mortality in Italy was 7.2%. In comparison, the case-fatality proportions
408 ranged from 1.6% (95% CI: 0.7–3.8%) [5] to 8.2% (95% CI 5.5–11.9%) [7] in the available global-level SRMAs.
409 Apart from age, underlying immunosuppressive conditions and setting, RSV positivity prevalence was
410 associated with the study location and sample size. Studies conducted in the north of Italy reported on average
411 a higher frequency of RSV. Compared with central and southern regions, mean winter temperature in northern
412 regions is lower [70]. Lower ambient temperature is a well-known positive predictor of RSV detection frequency
413 [71–73]. Smaller studies tended to report a higher RSV prevalence, which is consistent with the small study
414 effect. Fortunately, the double arcsine transformation prevents the undue large weights for these studies [74].
415 Future epidemiological studies should *a priori* determine an adequate number of subjects to be tested for RSV.
416 Despite a relatively high number of publications identified, most studies were limited to quantifying prevalence
417 of RSV following clinical request or in the context of influenza surveillance and were not specifically designed
418 to investigate RSV epidemiology and the associated BoD. Only a few papers went beyond mere positivity
419 prevalence reports. Currently, no cohort studies have evaluated the natural history of RSV disease in Italian
420 adults. In particular, it remains unclear how many RSV-positive adult outpatients develop complications and
421 being hospitalized. Some of these data gaps could be filled by a retrospective analysis of HDRs, but only if
422 matched with laboratory data. Indeed, many RSV-positive patients could be attributed alternative diagnostic
423 codes. Despite being highly specific and useful for the analysis of case-fatality rates, resource use and
424 temporal trends, studies of RSV-specific HDRs in adults inevitably lead to the underestimation of RSV BoD.
425 Cai et al. [24] have documented that the RSV-specific ICD-10 codes had a very low sensitivity of 6%.
426 Retrospective cohort studies based on HDRs only (i.e., without matching with laboratory data) would identify
427 an implausibly low number of RSV-specific diagnostic codes [35,75]. Another important data gap concerns
428 RSV epidemiology and BoD in residents of long-term care facilities, who may be the primary target population
429 for vaccination.

430 As we discussed earlier, the main limitations of the current evidence, which may underestimate RSV BoD,
431 include the predominant use of influenza-specific case definitions, reliance on a single specimen type, lack of
432 studies on the natural history of an RSV episode and some important BoD indicators like hospitalization rate.

433 At review level, we must acknowledge that some potentially relevant studies were not identified because their
434 primary goal was not related to RSV and thus were indexed alternatively.

435 The approval of the new vaccines depends on national authorities. This decision occurs within the framework
436 of developing national immunization programs and necessitates the utilization of assessment tools, such as
437 the health technology assessment (HTA) [76]. This process relies on a comprehensive understanding of the
438 epidemiology, BoD and pertinent economic analyses. Furthermore, HTA organizations are also evaluating the
439 implementation of guidelines that take into account, in the assessment of new technologies, also their societal
440 value [77]. This objective aligns with the "Broader value of vaccines" framework proposed by Bell et al. [78].
441 The framework encompasses various vaccine effects, including strictly health-related impacts, focusing on the
442 health of vaccinated individuals; general health effects, considering the influence of vaccination on the health
443 of the unvaccinated population; economic effects on the healthcare system, involving the costs and
444 corresponding budgetary compensations; and societal economic effects, evaluating broader economic of
445 vaccines impacts such as effects on productivity and macroeconomic growth from a societal perspective.

446 Incorporating these diverse effects is crucial in the HTA processes [77]. Enhancing the vaccines HTA involves
447 considering several additional factors, including broader cost offsets within the healthcare system, the
448 influence of vaccination on the quality of life of caregivers, its effectiveness in reducing viral transmission,
449 prevention of antimicrobial resistance, and the macroeconomic impacts of vaccination [79]. Moreover, there is
450 a requirement for novel economic models capable of capturing not only the simple cost/benefit ratio of
451 vaccination but also its broader value [80].

452 As part of future research and in light of the availability of new vaccines, it is evident that the generation of new
453 tools, evidence, and data is imperative to delve deeper into the long-term benefits arising from vaccination,
454 explore macroeconomic implications, understand community impact, and address issues pertaining to equity,
455 accessibility, and appropriate utilization. Moreover, it is crucial to emphasize greater involvement of citizens in
456 the implementation of vaccination decisions [81].

457 In conclusion, this article provides a comprehensive assessment of the RSV epidemiology and its BoD in the
458 Italian adult population. A systematic assessment of the full value of a new vaccination necessitates access to
459 national data regarding the epidemiological burden of the disease and the presence of effective surveillance
460 systems. Data plays a pivotal role in generating knowledge and evidence about diseases. Only through
461 evidence can priority actions for the control of infectious diseases be discerned, facilitating the promotion of
462 an informed decision-making process. This, in turn, supports the implementation of value-based immunization
463 strategies. In this paper, we comprehensively assessed RSV epidemiology and BoD in the Italian adult

464 population. Within its shortcomings, this SRMA supports the need to prioritize evaluation of the novel RSV
465 vaccines by Italian decision makers, especially for older adults and those affected by immunosuppressive
466 conditions.

467

468 **Data availability statement**

469

470 All raw data are within the manuscript and associated supporting materials. Further details may be obtained
471 from the corresponding author.

472

473 **Funding**

474

475 This research received no funding.

476

477 **Competing interests**

478

479 AD and GEC declare no conflicts of interest related to this work.

480

481 **References**

482

- 483 1. McLaughlin JM, Khan F, Begier E, Swerdlow DL, Jodar L, Falsey AR. Rates of medically attended
484 RSV among US adults: A systematic review and meta-analysis. *Open Forum Infect Dis.*
485 2022;9(7):ofac300. doi: 10.1093/ofid/ofac300.
- 486 2. Rafferty E, Paulden M, Buchan SA, Robinson JL, Bettinger JA, Kumar M, et al. Evaluating the
487 individual healthcare costs and burden of disease associated with RSV across age groups.
488 *Pharmacoeconomics.* 2022;40(6):633–645. doi: 10.1007/s40273-022-01142-w.
- 489 3. Osei-Yeboah R, Spreuwenberg P, Del Riccio M, Fischer TK, Egeskov-Cavling AM, Bøås H, et al.
490 Estimation of the number of RSV-associated hospitalisations in adults in the European Union. *J Infect*
491 *Dis.* 2023;228(11):1539–1548. doi: 10.1093/infdis/jjad189.

- 492 4. Du Y, Yan R, Wu X, Zhang X, Chen C, Jiang D, et al. Global burden and trends of respiratory syncytial
493 virus infection across different age groups from 1990 to 2019: A systematic analysis of the Global
494 Burden of Disease 2019 Study. *Int J Infect Dis.* 2023;135:70–76. doi: 10.1016/j.ijid.2023.08.008.
- 495 5. Shi T, Denouel A, Tietjen AK, Campbell I, Moran E, Li X, et al. Global disease burden estimates of
496 respiratory syncytial virus-associated acute respiratory infection in older adults in 2015: A systematic
497 review and meta-analysis. *J Infect Dis.* 2020;222(Suppl 7):S577–S583. doi: 10.1093/infdis/jiz059.
- 498 6. Tin Tin Htar M, Yerramalla MS, Moïsi JC, Swerdlow DL. The burden of respiratory syncytial virus in
499 adults: a systematic review and meta-analysis. *Epidemiol Infect.* 2020;148:e48. doi:
500 10.1017/S0950268820000400.
- 501 7. Nguyen-Van-Tam JS, O'Leary M, Martin ET, Heijnen E, Callendret B, Fleischhackl R, et al. Burden of
502 respiratory syncytial virus infection in older and high-risk adults: a systematic review and meta-analysis
503 of the evidence from developed countries. *Eur Respir Rev.* 2022;31(166):220105. doi:
504 10.1183/16000617.0105-2022.
- 505 8. Shi T, Vennard S, Jasiewicz F, Brogden R, Nair H; RESCEU Investigators. Disease burden estimates
506 of respiratory syncytial virus related acute respiratory infections in adults with comorbidity: A
507 systematic review and meta-analysis. *J Infect Dis.* 2022;226(Suppl 1):S17–S21. doi:
508 10.1093/infdis/jiab040.
- 509 9. Maggi S, Veronese N, Burgio M, Cammarata G, Ciuppa ME, Ciriminna S, et al. Rate of hospitalizations
510 and mortality of respiratory syncytial virus infection compared to influenza in older people: A systematic
511 review and meta-analysis. *Vaccines (Basel).* 2022;10(12):2092. doi: 10.3390/vaccines10122092.
- 512 10. Li Y, Kulkarni D, Begier E, Wahi-Singh P, Wahi-Singh B, Gessner B, et al. Adjusting for case under-
513 ascertainment in estimating RSV hospitalisation burden of older adults in high-income countries: A
514 systematic review and modelling study. *Infect Dis Ther.* 2023;12(4):1137-1149. doi: 10.1007/s40121-
515 023-00792-3.
- 516 11. Haynes AK, Manangan AP, Iwane MK, Sturm-Ramirez K, Homaira N, Brooks WA, et al. Respiratory
517 syncytial virus circulation in seven countries with Global Disease Detection Regional Centers. *J Infect*
518 *Dis.* 2013;208(Suppl 3):S246–S254. doi: 10.1093/infdis/jit515.
- 519 12. Staadegaard L, Caini S, Wangchuk S, Thapa B, de Almeida WAF, de Carvalho FC, et al. The global
520 epidemiology of RSV in community and hospitalized care: Findings from 15 countries. *Open Forum*
521 *Infect Dis.* 2021;8(7):ofab159. doi: 10.1093/ofid/ofab159.

- 522 13. Kotton CN. More protection against respiratory viral infection: Respiratory syncytial virus vaccines for
523 adults aged 60 years and older. *Ann Intern Med.* 2023;176(10):1419–1421. doi: 10.7326/M23-2196.
- 524 14. Centers for Disease Control and Prevention (CDC). Healthcare providers: RSV vaccination for adults
525 60 years of age and over. Available at: [https://www.cdc.gov/vaccines/vpd/rsv/hcp/older-](https://www.cdc.gov/vaccines/vpd/rsv/hcp/older-adults.html#:~:text=CDC%20recommends%20that%20adults%2060,RSV%20vaccination%20will%20be%20beneficial)
526 [adults.html#:~:text=CDC%20recommends%20that%20adults%2060,RSV%20vaccination%20will%20](https://www.cdc.gov/vaccines/vpd/rsv/hcp/older-adults.html#:~:text=CDC%20recommends%20that%20adults%2060,RSV%20vaccination%20will%20be%20beneficial)
527 [0be%20beneficial](https://www.cdc.gov/vaccines/vpd/rsv/hcp/older-adults.html#:~:text=CDC%20recommends%20that%20adults%2060,RSV%20vaccination%20will%20be%20beneficial).
- 528 15. United Kingdom Department of Health & Social Care. Respiratory syncytial virus (RSV) immunisation
529 programme for infants and older adults: JCVI full statement, 11 September 2023. Available at:
530 [https://www.gov.uk/government/publications/rsv-immunisation-programme-jcvi-advice-7-june-](https://www.gov.uk/government/publications/rsv-immunisation-programme-jcvi-advice-7-june-2023/respiratory-syncytial-virus-rsv-immunisation-programme-for-infants-and-older-adults-jcvi-full-statement-11-september-2023)
531 [2023/respiratory-syncytial-virus-rsv-immunisation-programme-for-infants-and-older-adults-jcvi-full-](https://www.gov.uk/government/publications/rsv-immunisation-programme-jcvi-advice-7-june-2023/respiratory-syncytial-virus-rsv-immunisation-programme-for-infants-and-older-adults-jcvi-full-statement-11-september-2023)
532 [statement-11-september-2023](https://www.gov.uk/government/publications/rsv-immunisation-programme-jcvi-advice-7-june-2023/respiratory-syncytial-virus-rsv-immunisation-programme-for-infants-and-older-adults-jcvi-full-statement-11-september-2023).
- 533 16. Levine MM, Levine OS. Influence of disease burden, public perception, and other factors on new
534 vaccine development, implementation, and continued use. *Lancet.* 1997;350(9088):1386–1392. doi:
535 10.1016/S0140-6736(97)03253-4.
- 536 17. Munn Z, Stern C, Aromataris E, Lockwood C, Jordan Z. What kind of systematic review should I
537 conduct? A proposed typology and guidance for systematic reviewers in the medical and health
538 sciences. *BMC Med Res Methodol.* 2018;18(1):5. doi: 10.1186/s12874-017-0468-4.
- 539 18. Barker TH, Migliavaca CB, Stein C, Colpani V, Falavigna M, Aromataris E, et al. Conducting
540 proportional meta-analysis in different types of systematic reviews: A guide for synthesisers of
541 evidence. *BMC Med Res Methodol.* 2021;21(1):189. doi: 10.1186/s12874-021-01381-z.
- 542 19. Boccalini S, Bonito B, Salvati C, Del Riccio M, Stancanelli E, Bruschi M, et al. Human respiratory
543 syncytial virus epidemiological burden in pediatric outpatients in Italy: A systematic review. *Vaccines*
544 (Basel). 2023;11(9):1484. doi: 10.3390/vaccines11091484.
- 545 20. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020
546 statement: an updated guideline for reporting systematic reviews. *BMJ.* 2021;372:n71. doi:
547 10.1136/bmj.n71.
- 548 21. Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. Methodological guidance for systematic reviews of
549 observational epidemiological studies reporting prevalence and cumulative incidence data. *Int J Evid*
550 *Based Healthc.* 2015;13(3):147-53. doi: 10.1097/XEB.0000000000000054.

- 551 22. Domnich A, Calabrò GE. Burden of RSV in Italian adults: Protocol for a systematic review and meta-
552 analysis. Available at: [https://www.protocols.io/view/burden-of-rsv-in-italian-adults-protocol-for-a-sys-
553 5qpvo32odv4o/v1](https://www.protocols.io/view/burden-of-rsv-in-italian-adults-protocol-for-a-sys-5qpvo32odv4o/v1).
- 554 23. Pisesky A, Benchimol EI, Wong CA, Hui C, Crowe M, Belair MA, et al. Incidence of hospitalization for
555 respiratory syncytial virus infection amongst children in Ontario, Canada: A population-based study
556 using validated health administrative data. *PLoS One*. 2016;11(3):e0150416. doi:
557 10.1371/journal.pone.0150416.
- 558 24. Cai W, Tolksdorf K, Hirve S, Schuler E, Zhang W, Haas W, et al. Evaluation of using ICD-10 code data
559 for respiratory syncytial virus surveillance. *Influenza Other Respir Viruses*. 2020;14(6):630–637. doi:
560 10.1111/irv.12665.
- 561 25. Haddaway NR, Collins AM, Coughlin D, Kirk S. The role of Google Scholar in evidence reviews and
562 its applicability to grey literature searching. *PLoS One*. 2015;10(9):e0138237. doi:
563 10.1371/journal.pone.0138237.
- 564 26. Hamid S, Winn A, Parikh R, Jones JM, McMorrow M, Prill MM, et al. Seasonality of respiratory syncytial
565 virus - United States, 2017-2023. *MMWR Morb Mortal Wkly Rep*. 2023;72(14):355–361. doi:
566 10.15585/mmwr.mm7214a1.
- 567 27. Bergeri I, Whelan MG, Ware H, Subissi L, Nardone A, Lewis HC, et al. Global SARS-CoV-2
568 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of
569 standardized population-based studies. *PLoS Med*. 2022;19(11):e1004107. doi:
570 10.1371/journal.pmed.1004107.
- 571 28. Rozenbaum MH, Begier E, Kurosky SK, Whelan J, Bem D, Pouwels KB, et al. Incidence of respiratory
572 syncytial virus infection in older adults: Limitations of current data. *Infect Dis Ther*. 2023;12(6):1487–
573 1504. doi: 10.1007/s40121-023-00802-4.
- 574 29. The Cochrane Collaboration. Cochrane handbook for systematic reviews of interventions, version
575 5.1.0, updated March 2011. Meta-regression. Available at: [https://handbook-5-
576 1.cochrane.org/chapter_9/9_6_4_meta_regression.htm#:~:text=Meta%2Dregression%20should%20
577 generally%20not,one%20or%20more%20explanatory%20variables](https://handbook-5-1.cochrane.org/chapter_9/9_6_4_meta_regression.htm#:~:text=Meta%2Dregression%20should%20generally%20not,one%20or%20more%20explanatory%20variables).
- 578 30. Rovida F, Percivalle E, Zavattoni M, Torsellini M, Sarasini A, Campanini G, et al. Monoclonal
579 antibodies versus reverse transcription-PCR for detection of respiratory viruses in a patient population
580 with respiratory tract infections admitted to hospital. *J Med Virol*. 2005;75(2):336–347. doi:
581 10.1002/jmv.20276.

- 582 31. Minosse C, Selleri M, Zaniratti MS, Cappiello G, Longo R, Schifano E, et al. Frequency of detection of
583 respiratory viruses in the lower respiratory tract of hospitalized adults. *J Clin Virol.* 2008;42(2):215–
584 220. doi: 10.1016/j.jcv.2008.01.012.
- 585 32. Puzelli S, Valdarchi C, Ciotti M, Dorrucchi M, Farchi F, Babakir-Mina M, et al. Viral causes of influenza-
586 like illness: Insight from a study during the winters 2004-2007. *J Med Virol.* 2009;81(12):2066-71. doi:
587 10.1002/jmv.21610.
- 588 33. Costa C, Libertucci D, Solidoro P, Sinesi F, Bergallo M, Margio S, et al. Rapid shell vial culture for the
589 detection of respiratory viruses from bronchoalveolar lavage in immunocompromised patients.
590 *Panminerva Med.* 2007;49(1):1–6.
- 591 34. Gerna G, Piralla A, Rovida F, Rognoni V, Marchi A, Locatelli F, et al. Correlation of rhinovirus load in
592 the respiratory tract and clinical symptoms in hospitalized immunocompetent and
593 immunocompromised patients. *J Med Virol.* 2009;81(8):1498–1507.
- 594 35. Cocchio S, Prandi GM, Furlan P, Venturato G, Saia M, Marcon T, et al. Respiratory syncytial virus in
595 Veneto Region: Analysis of hospital discharge records from 2007 to 2021. *Int J Environ Res Public*
596 *Health.* 2023;20(5):4565. doi: 10.3390/ijerph20054565.
- 597 36. Gambarino S, Mantovani S, Astegiano S, Libertucci D, Solidoro P, Baldi S, et al. Lower respiratory
598 tract viral infections in hospitalized adult patients. *Minerva Med.* 2009;100(5):349–355.
- 599 37. Paba P, Farchi F, Mortati E, Ciccozzi M, Piperno M, Perno CF, et al. Screening of respiratory
600 pathogens by Respiratory Multi Well System (MWS) r-gene™ assay in hospitalized patients. *New*
601 *Microbiol.* 2014;37(2):231–236.
- 602 38. Pierangeli A, Scagnolari C, Selvaggi C, Verzaro S, Spina MT, Bresciani E, et al. Rhinovirus frequently
603 detected in elderly adults attending an emergency department. *J Med Virol.* 2011;83(11):2043–2047.
604 doi: 10.1002/jmv.22205.
- 605 39. Nisii C, Meschi S, Selleri M, Bordi L, Castilletti C, Valli MB, et al. Frequency of detection of upper
606 respiratory tract viruses in patients tested for pandemic H1N1/09 viral infection. *J Clin Microbiol.*
607 2010;48(9):3383–3385. doi: 10.1128/JCM.01179-10.
- 608 40. Tramuto F, Maida CM, Napoli G, Mammaia C, Casuccio A, Cala' C, et al. Burden and viral aetiology
609 of influenza-like illness and acute respiratory infection in intensive care units. *Microbes Infect.*
610 2016;18(4):270–276. doi: 10.1016/j.micinf.2015.11.008.

- 611 41. Piralla A, Mariani B, Rovida F, Baldanti F. Frequency of respiratory viruses among patients admitted
612 to 26 Intensive Care Units in seven consecutive winter-spring seasons (2009-2016) in Northern Italy.
613 J Clin Virol. 2017;92:48–51. doi: 10.1016/j.jcv.2017.05.004.
- 614 42. Ansaldo F, De Florentiis D, Parodi V, Rappazzo E, Coppelli M, Martini M, et al. Bacterial carriage and
615 respiratory tract infections in subjects > or = 60 years during an influenza season: implications for the
616 epidemiology of community acquired pneumonia and influenza vaccine effectiveness. J Prev Med Hyg.
617 2012;53(2):94–97.
- 618 43. Bigliardi S, Morselli M, Potenza L, Riva G, Coluccio V, Maccaferri M, et al. Epidemiology and clinical
619 outcome of lower respiratory tract infections by respiratory syncytial virus or parainfluenza virus type
620 3 in adults receiving treatment for either acute leukemia or severe aplastic anemia: A retrospective
621 single center study. Ann Hematol. 2015;94(11):1931–1934. [https://doi.org/10.1007/s00277-015-2455-](https://doi.org/10.1007/s00277-015-2455-3)
622 3.
- 623 44. Mikulska M, Del Bono V, Gandolfo N, Dini S, Dominietto A, Di Grazia C, et al. Epidemiology of viral
624 respiratory tract infections in an outpatient haematology facility. Ann Hematol. 2014;93(4):669–676.
625 doi: 10.1007/s00277-013-1912-0.
- 626 45. Passi A, Pagani C, Gramegna D, Daffini R, Pollara CP, Signorini L, et al. Respiratory viruses are a
627 significant clinical problem in haematological patients with underestimated adverse outcome: A single
628 institution 9-years experience. Haematologica 2019;104(S2):29–30.
- 629 46. Pellegrinelli L, Galli C, Bubba L, Cereda D, Anselmi G, Binda S, et al. Respiratory syncytial virus in
630 influenza-like illness cases: Epidemiology and molecular analyses of four consecutive winter seasons
631 (2014-2015/2017-2018) in Lombardy (Northern Italy). J Med Virol. 2020;92(12):2999–3006. doi:
632 10.1002/jmv.25917.
- 633 47. Costa E, Giberti I, Scarpaleggia M, Massolo L, Massaro E, Trombetta CS, et al. Retrospective analysis
634 of viral diagnostics data of patients referred to the Policlinico San Martino Hospital in Genoa with acute
635 respiratory infection during eight sequential seasons (2014–2022). Presented at the 33rd European
636 Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Copenhagen (Denmark), 15–
637 18 April 2023.
- 638 48. Tramuto F, Maida CM, Di Naro D, Randazzo G, Vitale F, Restivo V, et al. Respiratory syncytial virus:
639 New challenges for molecular epidemiology surveillance and vaccination strategy in patients with
640 ILI/SARI. Vaccines (Basel). 2021;9(11):1334. doi: 10.3390/vaccines9111334.

- 641 49. Leli C, Di Matteo L, Gotta F, Vay D, Piceghello A, Cornaglia E, et al. Prevalence of respiratory viruses
642 by Multiplex PCR: a four-and-a-half year retrospective study in an Italian general hospital. *Infez Med.*
643 2021;29(1):94–101.
- 644 50. Ciotti M, Maurici M, Santoro V, Coppola L, Sarmati L, De Carolis G, et al. Viruses of respiratory tract:
645 an observational retrospective study on hospitalized patients in Rome, Italy. *Microorganisms.*
646 2020;8(4):501. doi: 10.3390/microorganisms8040501.
- 647 51. De Francesco MA, Pollara C, Gargiulo F, Giacomelli M, Caruso A. Circulation of respiratory viruses in
648 hospitalized adults before and during the COVID-19 pandemic in Brescia, Italy: A retrospective study.
649 *Int J Environ Res Public Health.* 2021;18(18):9525. doi: 10.3390/ijerph18189525.
- 650 52. Galli C, Pellegrinelli L, Del Castillo G, Forni G, Gandolfi CE, Mosillo M, et al. Self-sampling of
651 oropharyngeal swabs among healthcare workers for molecular detection of respiratory viruses: A
652 valuable approach for epidemiological studies and surveillance programs. *Front Public Health.*
653 2020;8:511669. doi: 10.3389/fpubh.2020.511669.
- 654 53. Domnich A, Orsi A, Ogliastro M, Ferrari A, Bruzzone B, Panatto D, Icardi G. Influenza-like illness
655 surveillance may underestimate the incidence of respiratory syncytial virus in adult outpatients. *Int J*
656 *Infect Dis.* Forthcoming.
- 657 54. Spagnolello O, Pierangeli A, Cedrone MC, Di Biagio V, Gentile M, Leonardi A, et al. Viral community
658 acquired pneumonia at the emergency department: Report from the pre COVID-19 age. *J Med Virol.*
659 2021;93(7):4399–4404. doi: 10.1002/jmv.26980.
- 660 55. Sberna G, Lalle E, Valli MB, Bordi L, Garbuglia AR, Amendola A. Changes in the Circulation of
661 Common Respiratory Pathogens among Hospitalized Patients with Influenza-like Illnesses in the Lazio
662 Region (Italy) during Fall Season of the Past Three Years. *Int J Environ Res Public Health.*
663 2022;19(10):5962. doi: 10.3390/ijerph19105962.
- 664 56. Pierangeli A, Piralla A, Uceda Renteria S, Giacomel G, Lunghi G, Pagani E, et al. Multicenter
665 epidemiological investigation and genetic characterization of respiratory syncytial virus and
666 metapneumovirus infections in the pre-pandemic 2018-2019 season in northern and central Italy. *Clin*
667 *Exp Med.* 2023;23(6):2725–2737. doi: 10.1007/s10238-022-00973-3.
- 668 57. Scagnolari C, Bitossi C, Frasca F, Viscido A, Oliveto G, Scordio M, et al. No detection of SARS-CoV-
669 2 in cystic fibrosis patients at the Regional (Lazio) Reference Center for CF in Italy. *J Cyst Fibros.*
670 2020;19(5):837–838. doi: 10.1016/j.jcf.2020.06.018.

- 671 58. Galli C, Pellegrinelli L, Bubba L, Primache V, Anselmi G, Delbue S, et al. When the COVID-19
672 pandemic surges during influenza season: Lessons learnt from the sentinel laboratory-based
673 surveillance of influenza-like illness in Lombardy during the 2019-2020 season. *Viruses*.
674 2021;13(4):695. doi: 10.3390/v13040695.
- 675 59. Treggiari D, Piubelli C, Formenti F, Silva R, Perandin F. Resurgence of respiratory virus after relaxation
676 of COVID-19 containment measures: A real-world data study from a regional hospital of Italy. *Int J*
677 *Microbiol*. 2022;2022:4915678. doi: 10.1155/2022/4915678.
- 678 60. Calderaro A, De Conto F, Buttrini M, Piccolo G, Montecchini S, Maccari C, et al. Human respiratory
679 viruses, including SARS-CoV-2, circulating in the winter season 2019-2020 in Parma, Northern Italy.
680 *Int J Infect Dis*. 2021;102:79–84. doi: 10.1016/j.ijid.2020.09.1473.
- 681 61. Milano G, Capitani E, Camarri A, Bova G, Capecchi PL, Lazzeri G, et al. Surveillance of influenza and
682 other airborne transmission viruses during the 2021/2022 season in hospitalized subjects in Tuscany,
683 Italy. *Vaccines (Basel)*. 2023;11(4):776. doi: 10.3390/vaccines11040776.
- 684 62. Panatto D, Domnich A, Lai PL, Ogliastro M, Bruzzone B, Galli C, et al. Epidemiology and molecular
685 characteristics of respiratory syncytial virus (RSV) among Italian community-dwelling adults, 2021/22
686 season. *BMC Infect Dis*. 2023;23(1):134. doi: 10.1186/s12879-023-08100-7.
- 687 63. Santus P, Radovanovic D, Gismondo MR, Rimoldi SG, Lombardi A, Danzo F, et al. Respiratory
688 syncytial virus burden and risk factors for severe disease in patients presenting to the emergency
689 department with flu-like symptoms or acute respiratory failure. *Respir Med*. 2023;218:107404. doi:
690 10.1016/j.rmed.2023.107404
- 691 64. Boattini M, Almeida A, Christaki E, Marques TM, Tosatto V, Bianco G, et al. Severity of RSV infection
692 in Southern European elderly patients during two consecutive winter seasons (2017-2018). *J Med*
693 *Virol*. 2021;93(8):5152–5157. doi: 10.1002/jmv.26938.
- 694 65. Almeida A, Boattini M, Christaki E, Moreira Marques T, Moreira I, Cruz L, et al. Comparative virulence
695 of seasonal viruses responsible for lower respiratory tract infections: a southern European multi-centre
696 cohort study of hospital admissions. *Infection*. 2021;49(3):483–490. doi: 10.1007/s15010-020-01569-
697 3.
- 698 66. Boattini M, Charrier L, Almeida A, Christaki E, Moreira Marques T, Tosatto V, et al. Burden of primary
699 influenza and respiratory syncytial virus pneumonia in hospitalised adults: insights from a 2-year multi-
700 centre cohort study (2017-2018). *Intern Med J*. 2023;53(3):404–408. doi: 10.1111/imj.15583.

- 701 67. Sáez-López E, Pechirra P, Costa I, Cristóvão P, Conde P, Machado A, et al. Performance of
702 surveillance case definitions for respiratory syncytial virus infections through the sentinel influenza
703 surveillance system, Portugal, 2010 to 2018. *Euro Surveill.* 2019;24:1900140. doi: 10.2807/1560-
704 7917.ES.2019.24.45.1900140.
- 705 68. Korsten K, Adriaenssens N, Coenen S, Butler CC, Verheij TJM, Bont LJ, et al. World Health
706 Organization influenza-like illness underestimates the burden of respiratory syncytial virus infection in
707 community-dwelling older adults. *J Infect Dis.* 2022;226:S71–S78. doi: 10.1093/infdis/jiab452.
- 708 69. McLaughlin JM, Khan F, Begier E, Swerdlow DL, Jodar L, Falsey AR. Rates of medically attended
709 RSV among US adults: A systematic review and meta-analysis. *Open Forum Infect Dis.*
710 2022;9(7):ofac300. doi: 10.1093/ofid/ofac300.
- 711 70. Fallani E, Orsi A, Signori A, Icardi G, Domnich A. An exploratory study to assess patterns of influenza-
712 and pneumonia-related mortality among the Italian elderly. *Hum Vaccin Immunother.*
713 2021;17(12):5514–5521. doi: 10.1080/21645515.2021.2005381.
- 714 71. Noyola DE, Mandeville PB. Effect of climatological factors on respiratory syncytial virus epidemics.
715 *Epidemiol Infect.* 2008;136(10):1328–1332. doi: 10.1017/S0950268807000143.
- 716 72. Lee MH, Mailepessov D, Yahya K, Loo LH, Maiwald M, Aik J. Air quality, meteorological variability and
717 pediatric respiratory syncytial virus infections in Singapore. *Sci Rep.* 2023;13(1):1001. doi:
718 10.1038/s41598-022-26184-0.
- 719 73. Radhakrishnan D, Ouedraogo A, Shariff SZ, McNally JD, Benchimol EI, Clemens KK. The association
720 between climate, geography and respiratory syncytial virus hospitalizations among children in Ontario,
721 Canada: a population-based study. *BMC Infect Dis.* 2020;20(1):157. doi: 10.1186/s12879-020-4882-
722 6.
- 723 74. Barendregt JJ, Doi SA, Lee YY, Norman RE, Vos T. Meta-analysis of prevalence. *J Epidemiol*
724 *Community Health.* 2013;67(11):974–978. doi: 10.1136/jech-2013-203104.
- 725 75. Amodio E, Vitale F, d'Angela D, Carrieri C, Polistena B, Spandonaro F, et al. Increased risk of
726 hospitalization for pneumonia in Italian adults from 2010 to 2019: Scientific evidence for a call to action.
727 *Vaccines (Basel).* 2023;11(1):187. doi: 10.3390/vaccines11010187.
- 728 76. O'Rourke B, Oortwijn W, Schuller T; International Joint Task Group. The new definition of health
729 technology assessment: A milestone in international collaboration. *Int J Technol Assess Health Care.*
730 2020;36(3):187–190. doi: 10.1017/S0266462320000215

- 731 77. Breslau RM, Cohen JT, Diaz J, Malcolm B, Neumann PJ. A review of HTA guidelines on societal and
732 novel value elements. *Int J Technol Assess Health Care*. 2023;39(1):e31. doi:
733 10.1017/S026646232300017X.
- 734 78. Bell E, Neri M, Steuten L. Towards a broader assessment of value in vaccines: The BRAVE way
735 forward. *Appl Health Econ Health Policy*. 2022;20(1):105–117. doi: 10.1007/s40258-021-00683-z.
- 736 79. Calabro' GE, Carini E, Tognetto A, Giacchetta I, Bonanno E, Mariani M, et al. The value(s) of
737 vaccination: Building the scientific evidence according to a value-based healthcare approach. *Front*
738 *Public Health*. 2022;10:786662. doi: 10.3389/fpubh.2022.786662.
- 739 80. Beck E, Biundo E, Devlin N, Doherty TM, Garcia-Ruiz AJ, Postma M, et al. Capturing the value of
740 vaccination within health technology assessment and health economics: Literature review and novel
741 conceptual framework. *Vaccine*. 2022;40(30):4008–4016. doi: 10.1016/j.vaccine.2022.04.050.
- 742 81. de Waure C, Calabrò GE, Ricciardi W; Value(s) of Vaccination Project Steering Committee.
743 Recommendations to drive a value-based decision-making on vaccination. *Expert Rev Vaccines*.
744 2022;21(3):289–296. doi: 10.1080/14760584.2022.2021880.

745 **Supporting information captions**

746

747 **S1 Fig. RSV positivity prevalence among Italian adults of any age, by study period in relation to the**
748 **COVID-19 pandemic.**

749 **S2 Fig. RSV positivity prevalence among Italian adults of any age, by study geographic area.**

750 **S3 Fig. RSV positivity prevalence among Italian adults of any age, by study sample size.**

751 **S4 Fig. Prevalence of RSV subtype B among Italian adults of any age (prevalence of RSV subtype A**
752 **may be computed as 1 – prevalence of RSV B).**

753 **S5 Fig. Frequency of viral co-detections among RSV-positive Italian adults of any age.**

754 **S6 Fig. In-hospital mortality among RSV-positive Italian adults of any age.**

755 **S1 Table. PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) checklist.**

756 **S2 Table. Algorithm for the automatic search, by citation database.**

757 **S3 Table. Excluded studies with reasons.**

758 **S4 Table. Syndromic definitions used the studies analyzed.**

759 **S5 Table. Risk of bias of the studies included according to the Joanna Briggs Institute (JBI) checklist**
760 **for prevalence/incidence studies.**

761 **S6 Table. RSV positivity prevalence among Italian adults of any age, by setting.**

762 **S7 Table. RSV positivity prevalence among Italian working-age adults, by setting.**

763 **S8 Table. RSV positivity prevalence among Italian older adults, by setting.**

764 **S9 Table. Meta-regression analysis to investigate sources of heterogeneity in RSV positivity**
765 **prevalence among Italian adults of any age.**

766 **S10 Table. RSV positivity prevalence among Italian adults, by subtype.**

767 **S11 Table. Frequency of viral co-detections among RSV-positive Italian adults of any age.**




Fig1





Fig2

Working-age adults



Older adults

